Myriad Genetics Inc
NASDAQ:MYGN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
15
28.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Myriad Genetics Inc
Myriad Genetics Inc
Change in Deffered Taxes
Myriad Genetics Inc
Change in Deffered Taxes Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Deffered Taxes | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Myriad Genetics Inc
NASDAQ:MYGN
|
Change in Deffered Taxes
-$5.3m
|
CAGR 3-Years
59%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Change in Deffered Taxes
-$2.1B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Change in Deffered Taxes
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Change in Deffered Taxes
-$1.5B
|
CAGR 3-Years
-93%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Change in Deffered Taxes
-$531.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
18%
|
CAGR 10-Years
-13%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Change in Deffered Taxes
-$763.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-30%
|
|
Myriad Genetics Inc
Glance View
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company is headquartered in Salt Lake City, Utah and currently employs 2,400 full-time employees. The firm primarily provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing the disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment, or assess a patient’s risk of disease progression, and includes corporate services, such as finance, human resources, legal and information technology. The firm discovers and commercializes genetic tests. The firm's products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight and Prequel, GeneSight, Vectra. The Company’s wholly owned subsidiaries include Myriad Genetic Laboratories, Inc., Assurex Health, Inc., Myriad Women’s Health, Inc, Myriad Genetics Espana SL, Myriad Genetics S.r.l., Myriad Genetics B.V. and Myriad Genetics GK.
See Also
What is Myriad Genetics Inc's Change in Deffered Taxes?
Change in Deffered Taxes
-5.3m
USD
Based on the financial report for Sep 30, 2024, Myriad Genetics Inc's Change in Deffered Taxes amounts to -5.3m USD.
What is Myriad Genetics Inc's Change in Deffered Taxes growth rate?
Change in Deffered Taxes CAGR 3Y
59%
Over the last year, the Change in Deffered Taxes growth was 50%. The average annual Change in Deffered Taxes growth rates for Myriad Genetics Inc have been 59% over the past three years .
You don't have any saved screeners yet
